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What is it? PTEN stands for
phosphatase and tensin homolog
deleted on chromosome 10, a tumor
suppressor gene located in a region of
human chromosome 10 that is
commonly deleted as many human
tumors progress.
What does it look like? PTEN looks
just like a tyrosine phosphatase, an
exciting discovery as many tumors are
caused by too much tyrosine kinase
activity. However, it dephosphorylates
tyrosine-phosphorylated proteins only
very poorly although a couple of
putative subtrates have been
identified. But in 1998, Jack Dixon’s
group showed that PTEN could
dephosphorylate a particular
phospholipid, phosphatidylinositol
3,4,5 trisphosphate or PtdIns(3,4,5)P3.
Is lipid phosphatase activity important?
Yes! PtdIns(3,4,5)P3 is produced by
phosphoinositide 3-kinase (PI3K),
which is important for insulin
signaling, cytoskeletal
rearrangements, differentiation,
migration, proliferation, survival… So
PTEN antagonizes PI3K by
converting PtdIns(3,4,5)P3 to an
inactive state. The lipid phosphatase
activity is probably more important
than the protein tyrosine phosphatase
activity for PTEN’s role as a tumor
suppressor: some PTEN mutants
found in tumors lack lipid
phosphatase activity but retain
tyrosine phosphatase activity.
Recently PTEN2 was described,
which is a membrane-associated,
testis-specific isoform. This enzyme
also dephosphorylates PtdIns(3,4,5)P3,
but seems to have a preference for the
related lipid PtdIns(3,5)P2, thereby
complicating matters.
What types of cancer do people with
PTEN mutations get? Sporadic PTEN
mutation occurs in more than 30% of
advanced brain and prostate cancers,
and endometrial cancers, and in a
range of others at lower frequency.
The overall frequency of mutation in
human cancer is similar to that of the
most famous tumor suppressor protein
p53. Germline PTEN mutations are
also found in some patients who
develop benign lesions throughout
their bodies, with an increased
incidence of breast, uterus and thyroid
cancers. Mice lacking both copies of
the gene die early in embryogenesis,
but heterozygote animals develop a
broad range of tumours similar to the
neoplasias seen in humans with one
mutated copy of PTEN. Interestingly,
heterozygote mice also develop an
autoimmune disorder through the
impaired death of activated T cells. 
How is PTEN regulated? Hmmm...
Despite more than 500 papers, there
is very little information on the
regulation of PTEN expression,
localization or activity. PTEN is
phosphorylated near its carboxyl
terminus on serine and threonine,
perhaps by casein kinase 2, which
may decrease its stability. The
carboxyl terminus of PTEN contains
a PDZ-binding domain, which may
regulate its localization to the plasma
membrane, where its substrate lipid
resides. 
Where can I find out more?
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PTEN converts the biologically active lipid
PtdIns(3,4,5)P3 to PtdIns(4,5)P2. The ribbon
diagram of the PTEN structure (Lee et al.,
Cell 1999, 99:323-334) is shown with the
active site in light blue. PtdIns(3,4,5)P3
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